Terlipressin on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage
Study Details
Study Description
Brief Summary
Terlipressin and somatostatin/octreotide are the first-line choices for the treatment of acute variceal bleeding in liver cirrhosis. Acute kidney injury can develop in patients presenting with acute variceal bleeding. On the other hand, evidence suggests that terlipressin can reverse hepatorenal syndrome. It has been hypothesized that terlipressin can protect the renal function in cirrhotic patients with acute variceal bleeding, except for control of bleeding.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Terlipressin group Cirrhotic patients with acute gastrointestinal bleeding received terlipressin with or without somatostatin/octreotide. |
Drug: Terlipressin
Continuous or intermittent intravenous infusion of terlipressin was given.
Other Names:
|
| Somatostatin/Octreotide group Cirrhotic patients with acute gastrointestinal bleeding received somatostatin and/or octreotide without terlipressin. |
Drug: Somatostatin
Continuous or intermittent intravenous infusion of somatostatin was given.
Other Names:
Drug: Octreotide
Continuous or intermittent intravenous infusion of octreotide was given.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Incidence of ICA-AKI and kidney function damage in cirrhotic patients with acute gastrointestinal bleeding [Through study completion, an average of 1-2 weeks]
ICA-AKI and kidney function damage
- Effect of ICA-AKI and kidney function damage on in-hospital mortality of cirrhotic patients with acute gastrointestinal bleeding [Through study completion, an average of 1-2 weeks]
In-hospital mortality
- Effect of terlipressin on the in-hospital mortality of cirrhotic patients with acute gastrointestinal bleeding with ICA-AKI and kidney function damage [Through study completion, an average of 1-2 weeks]
In-hospital mortality associated with ICA-AKI and kidney function damage
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Cirrhotic patients who were admitted between January 2010 and December 2018.
-
A diagnosis of acute gastrointestinal bleeding.
-
Patients who received terlipressin or somatostatin/octreotide.
-
Age or sex was not limited.
-
Use of endoscopy was not limited.
-
Comorbidity was not limited.
-
Malignancy was not limited.
Exclusion Criteria:
-
Renal parenchymal diseases.
-
Absence of baseline serum creatinine.
-
Absence of serum creatinine 3-5 days after terlipressin or somatostatin/octreotide.
-
Duration of terlipressin or somatostatin/octreotide was less 3 days.
-
Patients who underwent transjugular intrahepatic portosystemic shunt.
-
Patients who underwent surgical shunt, splenectomy with or without devascularization, or liver transplantation.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Center for Liver Cirrhosis, The Fifth Medical Center of PLA General Hospital | Beijing | Beijing | China | 100039 |
| 2 | Difficult & Complicated Liver Diseases and Artificial Liver Center, Beijing YouAn Hospital, Capital Medical University | Beijing | Beijing | China | 100069 |
| 3 | Liver Research Center, The First Affiliated Hospital of Fujian Medical University | Fuzhou | Fujian | China | 350005 |
| 4 | Department of Hepatobiliary Disease, 900 Hospital of the Joint Logistics Team (formerly called Fuzhou General Hospital) | Fuzhou | Fujian | China | 350025 |
| 5 | Department of Gastroenterology, The First Affiliated Hospital of Nanchang University | Nanchang | Jiangxi | China | 330006 |
| 6 | Department of Gastroenterology, The First Affiliated Hospital of China Medical University | Shenyang | Liaoning | China | 110001 |
| 7 | Department of Critical Care Medicine, The Sixth People's Hospital of Shenyang | Shenyang | Liaoning | China | 110006 |
| 8 | Department of Gastroenterology, Air Force Hospital of Northern Theater Command | Shenyang | Liaoning | China | 110042 |
| 9 | Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area) | Shenyang | Liaoning | China | 110840 |
| 10 | Department of Gastroenterology, Xi'an Central Hospital | Xi'an | Shaanxi | China | 710000 |
| 11 | Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University | Jinan | Shandong | China | 250021 |
| 12 | Eastern Hepatobiliary Hospital of the Second Military Medical University | Shanghai | Shanghai | China | |
| 13 | Department of Gastroenterology, General Hospital of Western Theater Command | Chengdu | Sichuan | China | 610083 |
| 14 | State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University | Hangzhou | Zhejiang | China | 310003 |
Sponsors and Collaborators
- General Hospital of Shenyang Military Region
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
- Zhang J, Rössle M, Zhou X, Deng J, Liu L, Qi X. Terlipressin for the treatment of hepatorenal syndrome: an overview of current evidence. Curr Med Res Opin. 2019 May;35(5):859-868. doi: 10.1080/03007995.2018.1552575. Epub 2019 Jan 4. Review.
- Zhou X, Tripathi D, Song T, Shao L, Han B, Zhu J, Han D, Liu F, Qi X. Terlipressin for the treatment of acute variceal bleeding: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018 Nov;97(48):e13437. doi: 10.1097/MD.0000000000013437.
- Zhou XM, Qi XS, Jia JD. [An evidence-based terlipressin therapy for gastroesophageal variceal hemorrhage]. Zhonghua Gan Zang Bing Za Zhi. 2018 Apr 20;26(4):245-248. doi: 10.3760/cma.j.issn.1007-3418.2018.04.002. Chinese.
- XHNKKY-VASO 2.0